<DOC>
	<DOCNO>NCT00152958</DOCNO>
	<brief_summary>The primary objective ass sustain efficacy patient respond 6 month treatment open-label pramipexole . Secondary objective measurement severity RLS , assessment early withdrawal phenomenon termination trial medication , augmentation treatment , sleepiness , quality life subjective wellbeing , physician 's clinical assessment symptom severity improvement . Another secondary objective safety tolerability treatment .</brief_summary>
	<brief_title>A Study Patients Suffering From Idiopathic Restless Legs Syndrome Who Responded Preceding , 6-month Treatment With Open-label Pramipexole Including Titration ( 0.125 , 0.25 , 0.5 , 0.75 mg Orally q.n . )</brief_title>
	<detailed_description />
	<mesh_term>Syndrome</mesh_term>
	<mesh_term>Psychomotor Agitation</mesh_term>
	<mesh_term>Restless Legs Syndrome</mesh_term>
	<mesh_term>Pramipexole</mesh_term>
	<criteria>Male female outpatient age 1880 Diagnosis idiopathic RLS accord Clinical RLS criteria International RLS Study Group RLSRS score &gt; 15 RLS symptom present least 2 3 day per week within last 3 month Written inform consent Women childbearing potential without adequate contraception , breastfeed Concomitant previous pharmacologically therapy RLS Clinically significant renal disease , and/or hepatic disease Any follow lab result screen : Hb , TSH , T3 T4 , clinically significantly normal range , positive urine drug screen Other clinically significant metabolicendocrine ( include diabetes mellitus require insulin therapy ) , haematological , gastrointestinal disease pulmonary disease . Poorly control cardiovascular disease History clinical sign peripheral neuropathy ( PNP ) , myelopathy multiple sclerosis neurological disease , potential secondarily cause RLS symptom , history clinical sign form epilepsy seizure Presence sleep disorder History schizophrenia psychotic disorder , history mental disorder , alcohol abuse drug addiction History clinical sign malign neoplasm Patients shiftworkschedule , otherwise unable follow regular sleepwake cycle enable use study medication time indicate Allergic pramipexole excipients</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>80 Years</maximum_age>
	<verification_date>November 2013</verification_date>
</DOC>